John W. Beck, CPA is currently Chief Financial Officer of Ritter Pharmaceuticals, Inc. He is also Chief Executive Officer of Wellspring Water Technologies and Chief Executive Officer of West Tech Medical, LLC, companies he co-founded. Previously, he served as Chief Financial Officer and Senior Vice President of Finance & Operations of Ardea Biosciences Inc., from 2008 until the acquisition by AstraZeneca in 2012 for $1.26B. He co-founded Metabasis Therapeutics Inc. in 1999 and served as its Chief Financial Officer from 2005 until 2008. In February 1994 he joined Neurocrine Biosciences, Inc., where he served as Director of Finance from May 1996 to April 1998 and played an important role in Neurocrine’s 1996 initial public offering. Mr. Beck received a BA in accounting from the University of Washington and also holds a ThB in theology from a Seattle, Washington-based seminary.
Matt Davidson, PhD
Dr. Davidson is a drug developer with an entrepreneurial mindset. He is the founder and former CEO of Verrica Pharmaceuticals (NASDAQ: VRCA), a drug company focused on medical dermatology. While CEO and Chairman of the Board at Verrica, he led the company from inception into pivotal Phase 3 clinical trials. He invented the core technology and helped raise over $100M in private and public financings. Recently, Dr. Davidson founded MGD Ventures, a Los Angeles based investment and advisory office focused on early-stage, clinically de-risked therapeutic assets. His academic research focused on immuno-oncology, autoimmunity, and cell therapy and was published in high-impact journals including The Lancet, Nature and Nature Medicine. Dr. Davidson graduated from UC Berkeley with a degree in molecular and cellular biology and earned his PhD in immunology from the Stanford University School of Medicine.
Miguel de los Rios, PhD
Miguel de los Rios is a passionate entrepreneur focused on building and developing novel therapeutics to satisfy unmet needs in human medicine. He received his PhD In biophysical chemistry and a BS in cell biology, both at UCSB. Currently, Miguel is CEO and co-founder of Endeavor Biomedicines. He was previously founding CEO at Rift Biotherapeutics, a therapeutic antibody company focused on modulating novel mechanisms to ignite the immune system against cancers. Miguel also served as Vice President of Research and Development at Sevion Therapeutics (formerly Fabrus, Inc.), a clinical stage therapeutics company focused in oncology and autoimmune disorders. Miguel founded Chimeros, Inc., a venture-backed biologics therapeutic company in 2003 while working to complete his Ph.D. at UCSB. At Chimeros, he served as both the Chief Executive Officer as well as the Chief Scientific Officer from 2003-2011, and was the inventor of the company’s core technologies. He continues to build and help launch companies whose missions are to radically disrupt current medical approaches. Miguel is a council member of the University of California Innovations Council where he works the entire UC system to aid system-wide innovation. He also advises several start-up biotechnology companies and venture capital firms. Miguel is lead author or inventor on 50 publications, patents and patent applications. He is also the founding blacksmith at Angel’s Forge.
Mike is Managing Principal of NINE75, a healthcare business and operations strategy company, and is an accomplished leader with over 20 years of broad experience in biopharma drug, medical device and healthcare development and corporate management. He has extensive strategic, financial and operational expertise, with experience in business financial operations, investor and media relations, portfolio planning, project and alliance management, protein biochemistry and process development. Most recently, Mike was CEO and President of NanoScopia, Inc., a medical device research and development company. Mike worked for nearly 20 years at ZymoGenetics, a Seattle-based biotech company and subsidiary of Bristol Myers-Squibb. Mike held positions of increasing responsibility in several departments during his tenure at ZymoGenetics, culminating in his role as Site Lead & Director of Operations. Mike holds a BBA in finance from the University of Notre Dame and a BS in genetics and cell biology from the University of Minnesota.
Dennis Kim, MD, MBA
Dr. Dennis Kim is a physician biotechnology executive with specialty training in endocrinology/metabolism spanning approximately 20 years of drug/product development and corporate strategy experience in the biotech and medical technology industries. Dr. Kim joined Emerald Health Sciences in March of 2019 as the company’s Chief Medical Officer and has taken a leadership role in clinical development and brings business development experience across Emerald’s portfolio of companies. Prior to this he was Chief Medical Officer at Zafgen for 7.5 years where he oversaw all aspects of clinical and medical affairs in the field of diabetes, obesity, and rare metabolic/genetic disorders. Prior to joining Zafgen, Dr. Kim held multiple senior-level positions at Orexigen Therapeutics (Sr. VP of Medical and Clinical Affairs), EnteroMedics (Chief Medical Officer) and Amylin Pharmaceuticals (Exec Director of Corporate Strategy). He holds an MD from the University of Health Sciences, The Chicago Medical School, an MBA from UCSD Rady School of Management and a B.S. in biology from the University of California at Los Angeles. His endocrinology/metabolism specialty fellow training was completed at UCSD School of Medicine.